Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) for Thoracic Trauma in the Setting of Platelet Dysfunction: A Translational Swine Study.

BACKGROUND In patients with non-compressible torso hemorrhage (NCTH), antiplatelet medications may lead to worse outcomes. Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) may potentially stabilize these patients, but currently major thoracic bleeding is a contraindication. The goal of this study was to determine if REBOA use for shock with major thoracic bleeding has worse outcomes in the setting of platelet dysfunction. METHODS Forty-one (41) male Yorkshire swine (60-80kg) underwent a 30% hemorrhage, then were randomized to three thoracic injuries, with and without Zone 1 REBOA occlusion: pulmonary parenchymal injury (PI), thoracic venous injury (VI), or subclavian artery injury (AI). All animals were given aspirin to produce platelet dysfunction. Following hemorrhage, thoracic injuries were induced (T0) and allowed to bleed freely. REBOA groups had Zone 1 occlusion, with deflation at T30. All groups received whole blood resuscitation at T30 and were euthanized at T90. Survival, total blood loss, hemodynamics, and arterial blood gas parameters were analyzed. RESULTS The PD+VI+REBOA group had 87.5% survival where PD+VI survival was 28.6%. No difference in survival was seen in the PI or AI groups. The PD+VI+REBOA group had total blood loss of 575.0±339.1mL, which was less than the PD+VI group (1086.0±532.1mL). There was no difference in total thoracic blood loss in the PI and AI groups with the addition of REBOA. All groups showed an equivalent decrease in HCO3 and base excess (BE) and increase in lactate at the end of the 30 minute pre-hospital phase. CONCLUSION In this study, Zone 1 REBOA improved survival and decreased blood loss with major venous injury, where no differences were seen in parenchymal and subclavian artery injuries. For thoracic bleeding without surgical capability, outcomes may be improved with REBOA, and these findings challenge current guidelines stating the contraindication of REBOA use in this setting. LEVEL OF EVIDENCE Level I Therapeutic/Care Management Study.